secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001193125-24-080641
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks appoints Dr. Neil Gallagher to board; 6th new director in 12 months
-----------------------------------------------------------------------------

- Dr. Gallagher joins board effective April 2, 2024 as Class I director, term to 2025 AGM.
- He will receive initial option grant for 74,000 common shares on appointment.
- Gallagher appointed to R&D committee; full committee composition updated (see filing).
- Gallagher is President & Head of R&D at Syndax Pharmaceuticals; ex-AbbVie, Amgen, Novartis.
- CEO says appointment supports advancement of '5 by 5' clinical programs and pipeline expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/0001193125-24-080641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524080641/d803711d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-080641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer